Is Thymosin Alpha-1 Legal in Minnesota?

HealthRX.com

Thymosin alpha-1 has no FDA approval and no clear compounding path

28-amino-acidLength of the thymosin alpha-1 peptide chain, in amino acidsSource: fda.gov

Print or save as PDF

Key numbers

  • 4 yes and 17 noFDA advisory committee vote on thymosin alpha-1 on December 4, 2024: yes and no votesSource: fda.gov, as cited Nov 7, 2026
  • 1.6 mgStrength of the finished thymosin alpha-1 injection sold outside the US (Zadaxin brand)Source: fda.gov, as cited Nov 7, 2026
  • 28-amino-acidLength of the thymosin alpha-1 peptide chain, in amino acidsSource: fda.gov, as cited Nov 7, 2026
  • FDA approval / None; no US application found [2]
  • Orphan designations / Four, a separate process from approval [2]
  • State-licensed pharmacy list / In none of the three categories; list updated May 14, 2026 [3]
  • Outsourcing facility list / Category 3, nominated without adequate support [4]
  • Advisory committee / Voted 4 yes, 17 no on December 4, 2024 [5]
  • HHS draft peptide policy / Not among the six named peptides [6]
  • Approved outside US / Italy, India, Hong Kong; two developer-tied reviews say 30 or more countries [2][7][8]
  • Minnesota law / Chapter 151 has sections on compounding (151.253) and legend drugs (151.37); its section headings do not name thymosin alpha-1 [1]

What is thymosin alpha-1, and is it FDA-approved?

Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide with an acetylated N-terminal end, originally isolated from thymosin fraction 5, a thymus extract; thymalfasin is the synthetic version, and Zadaxin is the brand of the finished 1.6 mg injection sold outside the US [2]. It is described as an immune modulator that augments T-cell function [9].

It has no FDA approval. A Drugs@FDA search found no US application for it, and its four US orphan drug designations come from a separate process and are not an approval [2].

Where does it sit in FDA's compounding rules?

On FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026), thymosin alpha-1 appears in none of the three categories [3]. It was previously in category 2, the tier for substances FDA believes may present significant safety risks, and now sits in the nominated-but-withdrawn table after the nominators withdrew; FDA's concerns about immunogenicity for certain routes, peptide impurities, and inadequate safety information remain posted [10]. FDA's category 1 policy does not apply to it [3].

On FDA's separate list for outsourcing facilities (updated March 21, 2025), it is in category 3, nominated without adequate support [4]. FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no on December 4, 2024, on both thymosin alpha-1 free base and thymosin alpha-1 acetate, and FDA proposed that the substance not be added to the pharmacy bulks list [5]. It is also not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [6].

Questions worth asking

Choose the questions you want to keep

What does Minnesota's pharmacy law say?

Minnesota's chapter 151 (the Pharmacy Practice and Wholesale Distribution Act) includes section 151.253 on compounding and section 151.37 on legend drugs and who may prescribe and possess them. Its table of sections does not name thymosin alpha-1 or peptides, so the federal status above is what determines how the substance is treated [1].

Is thymosin alpha-1 FDA-approved?
No. A Drugs@FDA search found no US application for thymosin alpha-1 (thymalfasin). It holds four US orphan drug designations, but orphan designation is a separate process from approval. [2]
Can a state-licensed pharmacy compound thymosin alpha-1?
It appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians, and FDA proposed not to add it to the pharmacy bulks list. On the outsourcing-facility list it is in category 3, nominated without adequate support. [3][4][5]
Is thymosin alpha-1 on the WADA prohibited list?
It is not named on WADA's 2026 Prohibited List. WADA does name thymosin-beta-4 and its derivatives such as TB-500, which are different peptides. [11]
Why does FDA have safety concerns about compounded thymosin alpha-1?
The posted concerns are a significant risk of immunogenicity for certain routes of administration, peptide impurity and characterization problems, and safety information FDA called inadequate to sufficiently understand the extent of any safety issues. The substance moved to the nominated-but-withdrawn table after the nominators withdrew, but those concerns remain posted. [10]
Show all 11 referencesHide references
Evidence overview for Is Thymosin Alpha-1 Legal in Minnesota?